Skip to main content

Table 1 The PAH Phenotype in MCT-Injected Rats: Near-Full Prevention by Early Treatment with VIP *

From: VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension

Measurements Control, untreated MCT + P value (post hoc)
   0 VIP ** ††
RV systolic pressure (mm Hg) 24.3 ± 2.4 61.4 ± 4.8 29.9 ± 1.8 < 0.05 < 0.05 NS
Arteriolar medial/luminal area 0.76 ± 0.07 3.9 ± 0.51 1.5 ± 0.2 < 0.05 < 0.05 NS
RV/(LV+septum) weight ratio 0.26 ± 0.01 0.56 ± 0.03 0.35 ± 0.01 < 0.05 < 0.05 NS
Lung inflammation (0-4) 0.20 ± 0.17 3.0 ± 0.26 0.3 ± 0.21 < 0.05 < 0.05 NS
  1. * VIP treatment was begun on the same day as MCT. ANOVA: p < 0.0001
  2. † MCT alone vs. control; ** VIP pretreatment vs. MCT alone; †† VIP pretreatment vs. control.